Special Issue

The Discovery of Novel Antimicrobial Agents to Combat Infections

Message from the Guest Editor

Infections in humans are significant individual and public health threats. The risks associated with infections worsen with new, emerging viral strains and antibiotic resistance to bacteria and fungi. Novel antimicrobial agents are desperately needed to overcome the urgent challenge of a lack of effective treatments for microbial infections. Many novel strategies are being actively pursued to combat microbial infections, including, but not limited to, new chemical compounds and biologics, bacteriophage therapies, immune-based and host-targeted forms, or molecules that modulate virulence or pathogenicity. This Special Issue aims to include exciting and new knowledge regarding novel antimicrobial agents to treat any infectious disease. We welcome manuscripts addressing all aspects (e.g., structure, characterization, spectrum and potency, mechanism, optimization, efficacy, PD/PK, safety, and toxicology) regarding the discovery and development of novel antimicrobial agents against various bacterial, viral, and fungal infections.

Guest Editor

Dr. Yuanpu Peter Di

Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA, USA

Deadline for manuscript submissions

30 November 2025

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/221858

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI